Colorectal Adenocarcinoma Clinical Trials

10 recruiting

Colorectal Adenocarcinoma Trials at a Glance

21 actively recruiting trials for colorectal adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 1 with 11 trials, with the heaviest enrollment activity in Los Angeles, Houston, and New York. Lead sponsors running colorectal adenocarcinoma studies include National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Akeso.

Browse colorectal adenocarcinoma trials by phase

Treatments under study

About Colorectal Adenocarcinoma Clinical Trials

Looking for clinical trials for Colorectal Adenocarcinoma? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Colorectal Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Colorectal Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 21 trials

Recruiting
Phase 1

A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

Advanced/Metastatic Colorectal Adenocarcinoma
Bayer130 enrolled21 locationsNCT07535112
Recruiting
Phase 1

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

Metastatic Pancreatic Ductal AdenocarcinomaStage IV Colorectal Cancer AJCC v7Stage IV Pancreatic Cancer AJCC v6 and v7+3 more
M.D. Anderson Cancer Center300 enrolled1 locationNCT02600949
Recruiting
Phase 1Phase 2

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

Stage IV Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Metastatic Colorectal Adenocarcinoma+2 more
National Cancer Institute (NCI)86 enrolled1 locationNCT07147231
Recruiting
Phase 1

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Stage IV Colorectal Cancer AJCC v8Metastatic Colorectal AdenocarcinomaRecurrent Colorectal Adenocarcinoma+1 more
National Cancer Institute (NCI)30 enrolled15 locationsNCT06102902
Recruiting
Phase 1

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Metastatic Colorectal Adenocarcinoma+1 more
National Cancer Institute (NCI)24 enrolled13 locationsNCT06696768
Recruiting
Not Applicable

Measurement of MMP-14 Protein, a Potential New Marker for Colorectal Cancer Detection, in Plasma Vesicles Named Exosomes

Colorectal Adenocarcinoma
CHU de Reims650 enrolled1 locationNCT06955767
Recruiting
Phase 3

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

Stage IV Colorectal Cancer AJCC v8Metastatic Colorectal Adenocarcinoma
Alliance for Clinical Trials in Oncology364 enrolled183 locationsNCT05673148
Recruiting
Phase 1

Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v8Metastatic Colorectal Adenocarcinoma
University of Southern California15 enrolled3 locationsNCT06336902
Recruiting
Not Applicable

Engage Psychosocial Intervention for Cancer Symptoms

Advanced Breast CancerAdvanced Prostate CancerAdvanced Lung Cancer+2 more
Duke University190 enrolled1 locationNCT06555588
Recruiting
Phase 3

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Colorectal Adenocarcinoma
Akeso560 enrolled2 locationsNCT06951503
Recruiting
Not Applicable

A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis

Colorectal AdenocarcinomaPeritoneal MetastasesAppendiceal Cancer
Yale University20 enrolled1 locationNCT07291180
Recruiting
Phase 1

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Locally Advanced Gastroesophageal Junction AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaStage IV Colorectal Cancer AJCC v8+26 more
Roswell Park Cancer Institute45 enrolled1 locationNCT04511039
Recruiting
Phase 1

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Breast CancerOvarian CancerProstate Cancer+8 more
Clasp Therapeutics, Inc.90 enrolled21 locationsNCT06778863
Recruiting

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

Stage I Colorectal Cancer AJCC v8Stage II Colorectal Cancer AJCC v8Stage IIA Colorectal Cancer AJCC v8+11 more
M.D. Anderson Cancer Center1,000 enrolled10 locationsNCT04739072
Recruiting
Phase 2

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma
Barbara Ann Karmanos Cancer Institute102 enrolled9 locationsNCT07130903
Recruiting
Phase 2

Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma

Colorectal Adenocarcinoma Metastatic in the Liver
Abramson Cancer Center at Penn Medicine27 enrolled1 locationNCT07082439
Recruiting
Phase 1

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

Liver CancerPancreatic CancerGastric Cancer+6 more
Arbele Pty Ltd68 enrolled3 locationsNCT05411133
Recruiting
Phase 1Phase 2

AK129 Combination Therapy for Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Advanced Solid TumorsColorectal Adenocarcinoma+1 more
Akeso230 enrolled1 locationNCT06943820
Recruiting
Phase 1

Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer

Colorectal Adenocarcinoma
Jonsson Comprehensive Cancer Center10 enrolled1 locationNCT06225011
Recruiting
Phase 2

Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

Colorectal CarcinomaColorectal NeoplasmsColorectal Cancer (CRC)+2 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS25 enrolled3 locationsNCT06640166